Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Differential Expression of Transferrin Receptor (TfR) in a Spectrum of Normal to Malignant Breast Tissues Implications for In Situ and Invasive Carcinoma

Differential Expression of Transferrin Receptor (TfR) in a Spectrum of Normal to Malignant Breast... RESEARCH ARTICLE Differential Expression of Transferrin Receptor (TfR) in a Spectrum of Normal to Malignant Breast Tissues: Implications for In Situ and Invasive Carcinoma Meenakshi Singh, MD,* Kimberly Mugler, MD,w Dulan W. Hailoo, MD,* Stephanie Burke, BS,* Barbara Nemesure, PhD,w Kathleen Torkko, PhD,z and Kenneth R. Shroyer, MD, PhD* Key Words: transferrin receptor, ductal carcinoma in situ, Abstract: Transferrin receptor (TfR), a type II transmembra- invasive breast carcinoma, immunohistochemistry nous receptor involved in iron uptake, is highly expressed in (Appl Immunohistochem Mol Morphol 2011;19:417–423) some cancers. We evaluated the expression of TfR in a spectrum of normal to malignant breast tissues to test the hypothesis that overexpression is associated with malignant transforma- tion. Expression of TfR was studied by immunohistochemistry he transferrin receptor (TfR, CD71) is a type II (CD71-Antibody, Thermo Fisher Scientific, Fremont, CA) for Ttransmembranous glycoprotein composed of 2 dis- percent positive cells (%) and intensity of staining (0 to 3 score) ulphide-bonded subunits (each 90,000 daltons) that in normal (n = 127), benign (n = 172), potentially premalig- binds and internalizes iron-loaded transferrin (Tf), to nant and in-situ carcinoma (n = 65), and invasive carcinoma provide the cell with iron, the essential micronutrient (n = 38). http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Differential Expression of Transferrin Receptor (TfR) in a Spectrum of Normal to Malignant Breast Tissues Implications for In Situ and Invasive Carcinoma

Download PDF
7 pages

Loading next page...
 
/lp/wolters-kluwer-health/differential-expression-of-transferrin-receptor-tfr-in-a-spectrum-of-8hOwL4Er0Q

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2011 by Lippincott Williams & Wilkins
ISSN
1541-2016
DOI
10.1097/PAI.0b013e318209716e
pmid
21297444
Publisher site
See Article on Publisher Site

Abstract

RESEARCH ARTICLE Differential Expression of Transferrin Receptor (TfR) in a Spectrum of Normal to Malignant Breast Tissues: Implications for In Situ and Invasive Carcinoma Meenakshi Singh, MD,* Kimberly Mugler, MD,w Dulan W. Hailoo, MD,* Stephanie Burke, BS,* Barbara Nemesure, PhD,w Kathleen Torkko, PhD,z and Kenneth R. Shroyer, MD, PhD* Key Words: transferrin receptor, ductal carcinoma in situ, Abstract: Transferrin receptor (TfR), a type II transmembra- invasive breast carcinoma, immunohistochemistry nous receptor involved in iron uptake, is highly expressed in (Appl Immunohistochem Mol Morphol 2011;19:417–423) some cancers. We evaluated the expression of TfR in a spectrum of normal to malignant breast tissues to test the hypothesis that overexpression is associated with malignant transforma- tion. Expression of TfR was studied by immunohistochemistry he transferrin receptor (TfR, CD71) is a type II (CD71-Antibody, Thermo Fisher Scientific, Fremont, CA) for Ttransmembranous glycoprotein composed of 2 dis- percent positive cells (%) and intensity of staining (0 to 3 score) ulphide-bonded subunits (each 90,000 daltons) that in normal (n = 127), benign (n = 172), potentially premalig- binds and internalizes iron-loaded transferrin (Tf), to nant and in-situ carcinoma (n = 65), and invasive carcinoma provide the cell with iron, the essential micronutrient (n = 38).

Journal

Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health

Published: Oct 1, 2011

There are no references for this article.